The maker of the high-selling tirzepatide injectable medication sold under the "We are an innovative company with an innovative product, and we price based on the value delivered to patients, physicians, and the healthcare system," Tucker said in an interview. "Tirzepatide is priced for the value it provides. Generic markets are separate...There is room for both segments.""Also, we offer both prefilled monthly pen and vial options, which gives patients some flexibility," said Tucker.His comments come ahead ...

与高盛同行：搭乘'魔法巴士'探访大型制药企业 20260228 摘要 GLP-1 与肥胖症市场：礼来与诺和诺德均预测 2030 年市场空间巨大， 口服药将激活新消费群体，司美格鲁肽仿制药影响有限。礼来认为口服 药营收占比可能高于当前模型预估的 30%。 口服减肥药商业化：诺和诺德强调减肥效果是关键驱动因素，而礼来认 为需求多样化市场中顶级减肥效果未必是主要驱动因素，并指出 Wegovy 用户因副作用管理问题难以达到最高剂量。 药品降价：近期下调标价至 675 美元更多是政府层面的考量，旨在优化 供应链结构、降低患者自付费用，并避免与竞品形成显著的价格差异对 比，而非净价层面的系统性改变。 PBM 改革：PBM 改革是多家公司关注的核心议题，可能打破回扣壁垒， 利好差异化药物准入。诺华与辉瑞均提到 PBM 改革会影响其在免疫学等 领域的研发策略。礼来强调缺乏 DTC 业务将错失机会。 默克公司催化剂：2026 年默克预计将有多个重要数据读出，覆盖 HIV、肿瘤学、TL1A 等领域。管理层预计到 2026 年底将降低约 350 亿美元的风险，目标对应的时间框架设定在 2030 年代中期。 诺华公司关注点：市场关注 ...

证券研究报告 | 2026年03月01日 2026年02月28日 2026年03月01日 美股市场速览 弱于大市 市场持续震荡，博弈聚焦半导体传媒 价格走势：整体持续震荡，大盘成长回落 本周，标普 500 指数-0.4%（上周+1.1%），纳斯达克综指-1.0%（上周+1.5%）。 风格：大盘价值（罗素 1000 价值+0.1%）＞小盘成长（罗素 2000 成长-0.6%） ＞大盘成长（罗素 1000 成长-0.8%）＞小盘价值（罗素 2000 价值-1.8%）。 15 个行业上涨，9 个行业下跌。上涨的主要有：家庭与个人用品（+3.3%）、 商业和专业服务（+3.3%）、公用事业（+2.9%）、食品与主要用品零售（+2.9%）、 制药生物科技和生命科学（+2.6%）；下跌的主要有：银行（-5.4%）、半导 体产品与设备（-4.5%）、汽车与汽车零部件（-2.3%）、耐用消费品与服装 （-2.1%）、综合金融（-1.0%）。 资金流向：整体小幅流出，博弈聚焦半导体传媒 本周，标普 500 成分股估算资金流（涨跌额 x 成交量）为-31.9（亿美元， 下同），上周为+43.9，近 4 周为-244.7，近 13 ...

Core Insights - The weight loss industry is increasingly dominated by GLP-1 medicines, with sales estimated at €50-60 billion last year and projected to reach €100 billion annually by the early 2030s [1][2]. Company Performance - Novo Nordisk's sales grew from 111.7 billion Danish krone in 2017 to 309 billion DKK last year, with net profits increasing from over 38 billion DKK to more than 102.4 billion DKK, indicating a tripling of both sales and profits in eight years [3]. - Eli Lilly's revenues rose from $28 billion in 2021 to over $65 billion last year, with net profits increasing from $5.6 billion to $20.6 billion during the same period [15]. Market Dynamics - Novo Nordisk's share price has declined over 60% in the past year due to unprecedented pricing pressure and increased competition from Eli Lilly's Mounjaro, which has gained market share [8][10]. - Novo's recent warning of a potential 13% drop in profits and sales this year was attributed to pricing pressures and increased competition [9]. Product Development - Novo Nordisk's new GLP-1 drug, CagriSema, showed a 23% weight loss over 84 weeks, which is less effective than Eli Lilly's Mounjaro, which achieved a 25.5% weight loss [11][12]. - Novo has received approval for a pill version of Wegovy, which is expected to be more attractive to consumers and cheaper to produce compared to injectable versions [25][26]. Competitive Landscape - The market is seeing an influx of new GLP-1 drugs from various pharmaceutical companies, which may lead to a hierarchy of medicines based on effectiveness and pricing [19][21]. - Generic versions of GLP-1 drugs are anticipated to enter the market soon, particularly in countries where patents have expired, which could further drive down prices [30][32]. Economic Impact - Novo Nordisk accounted for approximately 11% of Danish GDP growth last year, contributing significantly to employment and tax revenues [4][5]. - The rise of GLP-1 drugs is expected to impact various sectors, including food and beverage industries, as users may buy less food due to weight loss [36].

| 企业名称 强生 | 27 97 营业收入(亿美元) 941.93 | | | | --- | --- | --- | --- | | | | 营收同比增减 6% | 研发费用(亿美元) 146. 65 | | 罗氏 | 743.8 | 7% | 158. 12 | | 罗氏 | 743.8 | 7% | 158. 12 | | --- | --- | --- | --- | | 礼来 | 651.79 | 45% | 112 | | 默沙东 | 650. 1 | 1% | 121 | | 辉瑞 | 625. 79 | -2% | 104. 37 | | 阿斯利康 | 587. 39 | 8% | 94. 23 | | 诺华 | 545. 3 | 8% | 120 | | 赛诺菲 | 507.81 | 10% | 102. 54 | | 诺和诺德 | 489 | 6% | 75. 98 | | 葛兰素史克 | 427.94 | 7% | 68. 7 | 近期，强生、罗氏、礼来等多家跨国药企相继披露2025年业绩。其中，强生以942亿美元总营收位居首位，罗氏凭借五大重磅药物获得744.3亿美元收 入，位居第二 ...

There's a clear victor in the weight loss wars and it's Eli Liy. For about a century, Eli Liy and Novo Nordisk have competed in the diabetes market. Both were insulin giants.Neither clearly won. When the GLP1 boom began, investors assumed that a rising tide would lift both boats. Both companies already had blockbuster diabetes drugs.think Ompeic and Mount Jarro. So the thinking was that both companies would do quite well in the weight loss market too. At first, Novo Nordisk pulled ahead.The company won appr ...

Group 1: Caterpillar Inc - Caterpillar Inc reported strong earnings driven by increased demand in construction and mining sectors, with a revenue increase of 20% year-over-year [1] - The company’s operating profit margin improved to 15%, reflecting better cost management and pricing strategies [1] - Caterpillar's outlook remains positive, with projected revenue growth of 10% for the next fiscal year [1] Group 2: Eli Lilly and Company - Eli Lilly and Company announced a significant increase in revenue, primarily due to the strong performance of its diabetes and cancer treatment drugs, achieving a 25% increase compared to the previous year [1] - The company’s net income rose to $1.5 billion, indicating a robust profit margin of 30% [1] - Eli Lilly is expanding its research pipeline, with plans to invest $2 billion in new drug development over the next three years [1] Group 3: Walmart Inc - Walmart Inc experienced a revenue growth of 8% in the last quarter, driven by increased online sales and grocery demand [1] - The company’s e-commerce sales surged by 40%, highlighting a shift in consumer shopping behavior [1] - Walmart's operating income increased by 5%, reflecting effective cost control measures [1] Group 4: MasTec Inc - MasTec Inc reported a revenue increase of 15% year-over-year, supported by strong demand in the telecommunications and energy sectors [1] - The company’s net profit margin improved to 10%, driven by operational efficiencies [1] - MasTec is focusing on expanding its infrastructure projects, with an expected investment of $1 billion in the next fiscal year [1]

Core Insights - The article highlights five US blue-chip companies that have consistently paid dividends for over 100 years, indicating their financial durability and strong management practices [1][2]. Company Summaries - **Coca-Cola (NYSE: KO)**: Founded in 1892, Coca-Cola has paid dividends since 1893, currently yielding 2.58%. It is the world's largest beverage company with over 500 brands and serves more than 1.9 billion servings daily across 200 countries. Morgan Stanley rates it Overweight with a target price of $87 [1][2]. - **Colgate-Palmolive (NYSE: CL)**: This consumer staples giant has paid dividends since 1895, yielding 2.14%. The company focuses on Oral Care, Personal Care, Home Care, and Pet Nutrition, selling products under various well-known brands. Goldman Sachs has a Buy rating with a target price of $100 [1][2]. - **Eli Lilly (NYSE: LLY)**: A healthcare company that has paid dividends since 1885, currently yielding 0.59%. Eli Lilly develops and markets pharmaceutical products, including those for cardiometabolic health and oncology. Barclays rates it Overweight with a target price of $1,350 [2]. - **Exxon Mobil (NYSE: XOM)**: This integrated oil and gas company has paid dividends since 1882, with a current yield of 2.67%. Exxon is a leader in crude oil and natural gas production and has a strong capital allocation strategy. UBS has a Buy rating with a target price of $171 [2]. - **Stanley Black & Decker (NYSE: SWK)**: The largest tool company globally, it has paid dividends for over 145 years, currently yielding 3.68%. The company offers a wide range of tools and accessories and is expected to benefit from a potential economic slowdown. Citigroup has a Buy rating with a target price of $100 [2].

Core Viewpoint - Eli Lilly's Olumiant (baricitinib) has received a positive opinion from the European Medicines Agency's CHMP for expanded use in adolescents aged 12 to under 18 with severe alopecia areata, based on promising data from the Phase 3 BRAVE-AA-PEDS study [1][2]. Group 1: Clinical Study Results - The Phase 3 BRAVE-AA-PEDS study showed that 42.4% of adolescents treated with Olumiant achieved 80% or more scalp hair coverage at 36 weeks, compared to 4.5% in the placebo group [1]. - Near-complete scalp hair coverage (90%) was achieved by 36.5% of patients on Olumiant, while only 2.3% of those on placebo reached this level [1]. - Significant eyebrow regrowth was observed in 50% of patients on Olumiant, compared to 0% in the placebo group [1]. - Eyelash regrowth was reported in 42.9% of patients treated with Olumiant, versus 14.0% in the placebo group [1]. Group 2: Regulatory and Market Implications - The positive CHMP opinion is a step towards European regulatory approval, with a decision from the European Commission expected in the next one to two months [1]. - Lilly has also submitted Olumiant for approval in the U.S. for treating severe alopecia areata in adolescents, with a decision anticipated in the second half of 2026 [1][2]. - Olumiant is already approved for adult patients with severe alopecia areata in the U.S. and Europe, marking it as the first JAK inhibitor approved for this indication [1][2]. Group 3: Safety and Efficacy Profile - The safety profile of Olumiant in adolescents aligns with previous clinical trials for other conditions, such as juvenile idiopathic arthritis and atopic dermatitis [1]. - Over 14,600 patients have participated in clinical trials involving Olumiant, with more than 1,200 being children and adolescents [1]. - The ongoing BRAVE-AA-PEDS trial includes a cohort of children aged 6 to under 12 years, further expanding the understanding of Olumiant's safety and efficacy in younger populations [1].

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best GARP Stocks to Buy According to Analysts. RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market On February 25, RBC Capital initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Outperform rating and a $1,250 price target. The firm said Lilly’s obesity franchise is positioned to dominate the market through 2030. The analyst noted that investor sentiment remains broadly positive. At the same time, there “ ...